145 related articles for article (PubMed ID: 37992229)
1. Synthesis and Preclinical Evaluation of PSMA-Targeted
Santos JF; Braz MT; Raposinho P; Cleeren F; Cassells I; Leekens S; Cawthorne C; Mendes F; Fernandes C; Paulo A
Mol Pharm; 2024 Jan; 21(1):216-233. PubMed ID: 37992229
[TBL] [Abstract][Full Text] [Related]
2. Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus.
Fernandes C; Palma E; Silva F; Belchior A; Pinto CIG; Guerreiro JF; Botelho HM; Mendes F; Raposinho P; Paulo A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806239
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of [
Baun C; Dam JH; Hildebrandt MG; Ewald JD; Kristensen BW; Gammelsrød VS; Olsen BB; Thisgaard H
Sci Rep; 2023 Nov; 13(1):18837. PubMed ID: 37914790
[TBL] [Abstract][Full Text] [Related]
4. Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.
Rigby A; Firth G; Rivas C; Pham T; Kim J; Phanopoulos A; Wharton L; Ingham A; Li L; Ma MT; Orvig C; Blower PJ; Terry SYA; Abbate V
Bioconjug Chem; 2022 Jul; 33(7):1422-1436. PubMed ID: 35801668
[TBL] [Abstract][Full Text] [Related]
5. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
7. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
8. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
[TBL] [Abstract][Full Text] [Related]
9. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of
Figueiredo D; Fernandes C; Silva F; Palma E; Raposinho P; Belchior A; Vaz P; Paulo A
Molecules; 2021 Jan; 26(2):. PubMed ID: 33467760
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
13. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
16. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
